• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
By KEVIN CURRAN Aug 27, 2019 | 08:53 AM EDT
Stocks quotes in this article: JNJ, TEVA, MNK, ENDP

While $572 million is rarely viewed as a small figure, in terms of the penalty that was possible in the state of Oklahoma's opioid case against Johnson & Johnson (JNJ)  it could have been much worse.

Shares of the New Jersey-based pharmaceutical giant rose around 2% following the ruling by Oklahoma District Judge Thad Balkman that hit Johnson & Johnson with a hefty penalty for its role in the opioid crisis in the state.

"The opioid crisis is an eminent and menace to Oklahomans," Balkman said in a scathing decision. "The defendants caused an opioid crisis that is evidenced by increased rates of addiction, overdose deaths and neonatal abstinence syndrome in Oklahoma."

From the J&J #opioid opinion. $JNJ rebranded addiction as "pseudoaddiction" and recommended treating this problem with ever more pills. pic.twitter.com/qO2dg8dE6l

— Tom Hals (@tomhals) August 26, 2019

Balkman called J&J a "nuisance" to the public that aggressively marketed highly addictive substances and said its actions must be remedied by financial remuneration to the state, calling for a final total fine of $572 million.

However, as the state was originally seeking $17 billion from J&J, the amount of Balkman's fine should be encouraging to the company ahead of any appeal to reduce the penalty. Given the company's healthy cash position, the ruling is not crippling. J&J currently holds more than $15 billion in cash and cash equivalents and maintains a AAA credit rating.

"Even though the ruling went against the company, the stock is telling a different story in after-hours trading," Jim Cramer's Action Alerts PLUS team commented. "Shares are trading higher because that $572 million fine is well below the expectations many investors and analysts had into the announcement...as shareholders we are pleasantly surprised to see the sum this low." J&J is a holding of Cramer's Action Alerts PLUS charitable trust.

Indeed, Morgan Stanley noted that the consensus expectation ahead of the decision was a fine in the range of $1.5 billion to $2 billion, adding to downside pressure on the stock in recent weeks.

Morgan Stanley's pharmaceutical analyst expected that not only Johnson & Johnson but also Teva Pharmaceutical Industries  (TEVA) , Mallinckrodt (MNK)   and Endo Pharmaceuticals (ENDP) to trade higher on the relatively dovish decision and prospects of an appeal. IN pre-market hours, that forecast has proven true.

Despite what is considered a relatively minor fine, the company has stated its intention to appeal the decision vigorously.

"Janssen did not cause the opioid crisis in Oklahoma, and neither the facts nor the law support this outcome," Johnson & Johnson general counsel Michael Ullmann said. "We recognize the opioid crisis is a tremendously complex public health issue and we have deep sympathy for everyone affected. We are working with partners to find ways to help those in need."

Ullmann added that the U.S. Food and Drug Administration's (FDA) approval of each of its opiate drugs and strong regulations on labeling should protect the company from harsh penalties in the future and he remains confident in J&J's chances on an appeal.

"This judgment is a misapplication of public nuisance law that has already been rejected by judges in other states," Ullmann said. "The unprecedented award for the State's 'abatement plan' has sweeping ramifications for many industries and bears no relation to the Company's medicines or conduct."

Bigger Fires to Put Out

Still, J&J investors are not out of the woods yet.

"With over 2,000 similar lawsuits outstanding against the company, we expect this issue could take years to resolve," Stifel analyst Rick Wise said. "The challenge for the stock remains occasionally uncomfortable headlines as cases/appeals are won or lost."

Most prominent in the next few years will be the ongoing appeal of the Oklahoma decision and the coming federal case in Ohio set for October.

"Looking forward, an appeal process could extend into 2021; should it proceed to the U.S. Supreme Court, we could be looking at an additional 1-2 years," Jefferies analyst Joanne Wuensch said. "Next, J&J is part of a Federal MDL (Multi-District Litigation) that bundles opioid cases for 20+ companies, expected to begin on October 21."

The multidistrict case set to take place in Ohio will bring together thousands of suits into one landmark case involving numerous alleged statute violations, including RICO laws, and could set a strong precedent for further penalties. The case will be held in federal court and is likely to serve as a better bellwether for coming opioid cases the drug industry faces.

The Ohio trial has the added wrinkle of being a jury trial, which are generally less friendly to defendants, especially if the perception that JNJ got off easy in Oklahoma persists.

Johnson & Johnson has shown a preference to fight these cases in court given its belief that it is not responsible for the ills of the opioid crisis, but noted in a press release that it would still consider a settlement, as has been the hope of plaintiffs in that case.

With a great degree of uncertainty surrounding any appeal in Oklahoma and the larger coming case in Ohio as well as concerns about ongoing talc litigation facing J&J, analysts warned not to get carried away in thinking that the bad news has been shaken out.

"We caution against extrapolating too far in either the positive or negative direction," Morgan Stanley analyst David Lewis said. "The eventual outcome and/or settlement is far from clear given JNJ plans to appeal the Oklahoma decision, the decision is not definitively precedent-setting, and the decision cannot be used to imply the outcomes of other states or Municipalities."

Lewis said he expects the total fine exposure could reach as high as $16 billion, which would put an end to the initial positive reaction to the latest decision. 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Corporate Governance | Regulation | Litigation | Investing | Markets | Stocks | Pharmaceuticals | Real Money | Analyst Actions | Stock of the Day | ESG Investing

More from Stocks

The Chasing Slows on Wall Street

James "Rev Shark" DePorre
Mar 24, 2023 4:34 PM EDT

After Deutsche Bank shakes up investors, market cools a bit, which might be a healthy development.

Stay Away From These Types of Stocks, They're Radioactive

Jim Collins
Mar 24, 2023 2:35 PM EDT

Here's what you're better off buying. I certainly have.

GE Looks Poised for a Pullback: How to Trade It Now

Bruce Kamich
Mar 24, 2023 1:45 PM EDT

The shares stopped short of my price targets.

It's Not Whether the Next Shoe Will Drop, But Where and When

Bret Jensen
Mar 24, 2023 11:30 AM EDT

A few months of anxiety likely lies ahead of us, and caution remains the watchword of the day.

The Good, Bad and Ugly: What's Happening and What Investors Need to Do

Stephen Guilfoyle
Mar 24, 2023 10:45 AM EDT

Right now I have more in cash, or equivalents, than in equities. Ever hear of a Wall Street guy saying that before?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login